louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05602038: Comparative Study on the Effect of Quadratus Lumborum Block Versus Intrathecal Morphine on the Incidence of Chronic Pain Post Caesarean Section in a University Hospital of Middle-income Country
Official title: Comparative Study on the Effect of Quadratus Lumborum Block Versus Intrathecal Morphine on the Incidence of Chronic Pain Post Caesarean Section in a University Hospital of Middle-income Country; A Randomized Control Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Post Cesarean Pain
Lead sponsor: Menoufia University
Sponsor class: OTHER
First posted: 2022-11-01
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized control study
Primary purpose: TREATMENT

Brief summary: The aim of this study is to compare the incidence of CPSCP in patients receiving QLB quadratus lumborum block and ITM versus control as a primary outcome and associated risk factors that might predispose patients to develop CPSCP.

Detailed description: The aim of this study is to compare the incidence of chronic post cesarean pain in patients receiving quadratus laborum block and and intrathecal morphine versus control as a primary

Study design:

Patients will be randomly allocated to the procedure through closed envelopes and so syringes and medication will be prepared and labelled by anesthetist other than the anesthetist giving the block Patients will be randomly allocated to the procedure through closed envelopes and so syringes and medication will be prepared and labelled by anesthetist other than the anesthetist giving the block Data will be collected regarding the demographic data, gestational stage, parity and number of previous cesarean section, previous abdominal surgeries, and narcotic consumption.

Postoperative pain day 1 and day2 will be followed by anesthetist who is blinded to the applied technique used. Follow up for the subsequent period of observation (2,4and 6 months) will be done by the department secretary who will contact the patients by phone to ask them if there is any "concern" after the operation. If the patient refers to a pain at the surgical site that has been lasting for the past three months a call will be conducted by the anesthetist and a referral schedule will be appointed to the pain clinic consultant for further evaluation

Eligibility criteria: Inclusion Criteria:

* patients admitted to the operating theatre for elective caesarean section

Exclusion Criteria:

* lack of informed consent
* Allergy to drugs used during the study
* Depression and epilepsy that required antidepressants or anticonvulsants
* known coagulopathy as a contraindication for spinal anesthesia

Primary outcomes:
measure: Visual analogue scale
timeFrame: Six months
Secondary outcomes:
measure: narcotic consumption
timeFrame: 48 hours
Other outcomes:
Locations:
city: Menoufia
country: Egypt
facility: Menoufia University
Study officials:
References:
Clinical trial NCT00906438: Effects of 2006-RD-05 on Salivary and Serum Immunoglobulin A (IgA) Levels in Healthy Subjects
Official title: Effects of 2006-RD-05 on Salivary and Serum IgA Levels in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: innoVactiv Inc.
Sponsor class: INDUSTRY
First posted: 2009-05-21
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: It is already known from animal studies that the study drug can improve mucosal immunity as shown by increased serum and mucosal IgA secretion. This study will evaluate the safety of an oral intake of the natural product 2006-RD-05 at the recommended daily dose of 300 mg. In addition, this trial will aim to determine if this intake is able ot improve serum and salivary IgA synthesis.


Eligibility criteria: Inclusion Criteria:

* Men or women aged 18 - 60
* In good health
* BMI between 20 and 30 kg/m2
* Non-smoking

Exclusion Criteria:

* Allergic to study drug
* Use of immune-modulating drugs
* Uncontrolled hypertension (Systolic \> 140 or diastolic \> 90)
* Women of childbearing age not using proper contraception, that is pregnant or breastfeeding

Primary outcomes:
measure: Occurrence of adverse events
timeFrame: Baseline, 14 days, 28 days
Secondary outcomes:
measure: Serum IgA titers
timeFrame: Baseline, 14 days, 28 days
measure: Salivary IgA titers
timeFrame: Baseline, 14 days, 28 days
Other outcomes:
Locations:
city: Quebec
country: Canada
facility: Institut des Nutraceutiques et des Aliments Fonctionnels (INAF)
Study officials:
References:
Clinical trial NCT04997538: Study on Susceptibility Genes of Anterior Cruciate Ligament, Patella Dislocation and Discoid Meniscus
Official title: Study on Susceptibility Genes of Anterior Cruciate Ligament, Patella Dislocation and Discoid Meniscus
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Gene Abnormality
Meniscus Injury
Cruciate Ligament Rupture
Keywords: gene
exon
cruciate ligament
patellar
meniscus injury
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2021-08-09
Enrollment: 3000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with ACL injury surgery, patients after sports injury, knee joint shape abnormality, and patients with family genetic predisposition to sports related diseases

Brief summary: Genomes of all sports medicine-related genes will be exome sequenced to find relevant gene mutations. To further study the molecular mechanisms and signaling pathways related to sports injury. To search for genetic risk factors of injury and put forward related scientific hypotheses. To demonstrate the importance of mutation or polymorphism of related genes in injury.


Eligibility criteria: Inclusion Criteria:

1. Patients with joint sports injuries.
2. Follow-up patients after sports injury.
3. Patients with genetic predisposition to sports injuries.
4. Patients with family genetic predisposition to exercise-related diseases and their relatives.

Exclusion Criteria:

1. Patients with joint damage caused by external force.
2. The patient is accompanied by other injuries at the same time.

Primary outcomes:
measure: Magnetic resonance imaging (MRI)
timeFrame: Before the operation
measure: Magnetic resonance imaging (MRI)
timeFrame: an average of 1 year
measure: Radiographs
timeFrame: Before the operation
measure: Radiographs
timeFrame: an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Institute of Sports Medicine, Peking University Third Hospital
state: Beijing
Study officials:
affiliation: Peking University Third Hospital
name: Lin Lin
role: STUDY_DIRECTOR
References:
Clinical trial NCT01273038: Clinical Investigation for New Filter to Ostomy Bags
Official title: Clinical Investigation of Filter Improvement for New Filter to Ostomy Bags
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colostomy
Lead sponsor: Coloplast A/S
Sponsor class: INDUSTRY
First posted: 2011-01-10
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of the current clinical investigation is to evaluate a new filter.

Detailed description: The new filter has been developed in order to significantly reduce problems with ballooning and other problems related to filter performance in people with a stoma.

Eligibility criteria: Inclusion Criteria:

* Be at least 18 years of age and have full legal capacity.
* Have given written informed consent.
* Be able to fill in the Case Report Form.
* Be colostomy operated and have had a stoma for at least 6 months.
* Experience ballooning at least once per week.
* Be able to manage the bags themselves (application, removal).
* Be able to use a flat base plate.
* Have a stoma with a diameter less than 60 mm

Exclusion Criteria:

* Persons who irrigate
* Currently suffer from peristomal skin problems (i.e. bleeding or broken skin).
* Currently receiving or have within the past 2 months received radio- and/or chemotherapy.
* Pregnant or breastfeeding.
* Participate in other test at the same time.

Primary outcomes:
measure: Frequency of Ballooning in the Morfeus and SenSura Test Period.
timeFrame: Daily or at every change of bag in a period of a maximum of 28 days
Secondary outcomes:
Other outcomes:
Locations:
city: Humlebaek
country: Denmark
facility: Coloplast A/S
Study officials:
affiliation: Coloplast A/S
name: Daniel Carter, MSc
role: STUDY_CHAIR
References:
Clinical trial NCT02930538: Can Postoperative Outcomes be Predicted From Asking OSA Screening Questions Pre-operatively?
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Obstructive Sleep Apnea
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
First posted: 2016-10-12
Enrollment: 0
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children having surgery at Nationwide Children's Hosp (NCH).

Brief summary: The proposed research will determine whether a 6-item screening questionnaire previously shown to correlate with moderate or severe OSA is useful for predicting postoperative outcomes in children undergoing surgery under general anesthesia.

Detailed description: The survey will be administered preoperatively in the ENT clinic or the preoperative surgical unit. The following data will also be recorded: patient demographics (age, gender, BMI), surgical procedure, length of procedure and anesthetic, and smoking exposure. Based on differences in postoperative outcomes (e.g., supplemental oxygen requirement in the PACU) observed in the derivation cohort for the 6-item questionnaire, the study will enroll 1,000 patients to attain sufficient power for evaluating the 6-item questionnaire in the overall cohort and in demographically or clinically defined subgroups.

Eligibility criteria: Inclusion Criteria:

* The study will include all who are presenting for surgery to the main operating room, ambulatory surgical center or procedure center at Nationwide Children's Hospital.

Exclusion Criteria:

* Emergency surgery and any caregiver or patient refusal.

Primary outcomes:
measure: Liters of Oxygen
timeFrame: 1 hr post-op
Secondary outcomes:
measure: Narcotic usage in mg
timeFrame: 1 hr post-op
measure: PACU length of stay
timeFrame: 1-2 hr post-op
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
References:
Clinical trial NCT01460238: Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia
Official title: Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Lymphocytic Leukemia
Keywords: Lipoprotein Lipase
Chronic Lymphocytic Leukemia
CLL
Lead sponsor: Dartmouth-Hitchcock Medical Center
Sponsor class: OTHER
Collaborators: name: American Cancer Society, Inc.
First posted: 2011-10-26
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center with CLL

Brief summary: The investigators hypothesize that Lipoprotein Lipase (LPL) expression on Chronic Lymphocytic Leukemia (CLL) cells will predict a more aggressive clinical course. The results from this proposal will validate the use of a novel antibody developed at Dartmouth-Hitchcock in CLL and will predict CLL patients that have a more aggressive form of the disease. The investigators work will also provide direct evidence that LPL is expressed on CLL cells and provides a critical source of fatty acids required by the CLL cells to grow and survive. Fatty acid metabolism may become a therapeutic target in CLL in the future.

Detailed description: The investigators plan to use a novel antibody developed at Dartmouth-Hitchcock Medical Center to characterize the expression of LPL in CLL. Peripheral blood from CLL patients will be analyzed by flow cytometry to detect the expression of LPL and to investigate if LPL expression correlates with a more aggressive type of CLL. The investigators propose that LPL protein expression on CLL cells is prognostic and that LPL and other proteins involved in fatty acid metabolism are critical for CLL cells to survive.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of CLL as per National Cancer Institute Working Group Guidelines
* Patients undergoing routine blood draws as part of their ongoing follow up for CLL
* 18 years or older
* Ability to provide consent in English
* Patient must have measurable disease as defined by an absolute lymphocyte count greater than 5,000/mm3 or have archived lymph node or bone marrow with CLL involvement.

Exclusion Criteria:

* Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for their CLL,
* other hematologic malignancy or other disease process within the past 6 months are excluded.

Primary outcomes:
measure: LPL Protein Expression
timeFrame: 1 year
Secondary outcomes:
measure: Fatty acid acquisition and synthesis
timeFrame: 1 year
Other outcomes:
Locations:
city: Lebanon
country: United States
facility: Dartmouth-Hitchcock Medical Center
state: New Hampshire
Study officials:
affiliation: Dartmouth-Hitchcock Medical Center
name: Frederick Lansigan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05603338: Naturally Banded Sleeve Gastrectomy
Official title: Naturally Banded Sleeve Gastrectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity, Morbid
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2022-11-02
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the idea is to use an omental flap or round ligament as a natural band in stead of synesthetic band in bariatric procedures, mainly gastric sleeve

Detailed description: the idea is to use an omental flap or round ligament as a natural band in stead of synesthetic band in bariatric procedures, mainly gastric sleeve

Eligibility criteria: Inclusion Criteria:

* obese patients with BMI more than 40 with or without co-morbidity or more than 35 with co-morbidity
* patients fit for laparoscopic surgery
* give approval to share in the study
* previous restrictive bariatric procedure

Exclusion Criteria:

* patients unfit for surgery
* patients aged less than 18 and older than 60
* patient with previous upper abdominal surgery either for obesity or other diseases

Primary outcomes:
measure: the effect on weight loss
timeFrame: 12 months
measure: the size of gastric pouch at one year
timeFrame: 12 months
Secondary outcomes:
measure: the effect on comorbidities
timeFrame: 12 monthts
measure: operative time
timeFrame: 6 hours
measure: the incidences of complications
timeFrame: 12 monthss
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Minia university hospital
Study officials:
References:
Clinical trial NCT01800708: Cataract Surgery With Intracameral Triamcinolone in Infants
Official title: The Use of Intraocular Triamcinolone in the Perioperative Period of Congenital Cataract Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cataract
Lead sponsor: Fundação Altino Ventura
Sponsor class: OTHER
First posted: 2013-02-28
Enrollment: 60
Sex: ALL
Minimum age (years): 6
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the present study is to investigate the outcomes of congenital cataract surgery when injecting intraoperative intracameral triamcinolone versus the postoperative use of oral prednisolone.

This is a prospective, randomized clinical trial. Sixty children will be submitted to congenital cataract surgery younger than 2 years of age. They will be randomly divided in two groups. The study group will receive an intraoperative intracameral triamcinolone acetonide injection. The control group will receive prednisolone syrup postoperatively. The surgical outcomes will be assessed after one year.


Eligibility criteria: Inclusion Criteria:

* Patients younger than 2 years of age
* Unilateral or bilateral congenital cataracts compromising the red reflex

Exclusion Criteria:

* Corneal opacity
* Glaucoma
* Aniridia
* Subluxated cataract
* Traumatic cataract
* Complex microphthalmia
* Persistant hyperplastic primary vitreous
* Retinal detachment
* Patients with intraoperative complications, such as IOL implanted in the sulcus

Primary outcomes:
measure: Visual axis obscuration
timeFrame: 1 year after surgery
measure: Intraocular pressure
timeFrame: 1 year after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Recife
country: Brazil
facility: Altino Ventura Foundation
state: Pernambuco
Study officials:
affiliation: Fundação Altino Ventura
name: Marcelo Ventura, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03459508: Ocular Findings in Women With Primary Antiphospholipid Syndrome
Official title: Ocular Findings in Women With Primary Antiphospholipid Syndrome and Their Association to Bad Obstetric Outcome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Primary Antiphospholipid Syndrome
Keywords: Antiphospholipid Syndrome - Bad obstetric history - Ocular
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-03-09
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Female patients (inpatient or outpatient) with primary antiphospholipid syndrome at Kasr-Alainy hospital (The Cairo University Hospital)

Brief summary: Antiphospholipid antibody syndrome (APS) is an autoimmune disease characterized by systemic thrombosis and bad obstetric history. APS secondary to another medical disorder is the most common. Visual and ocular changes e.g. vaso-occlusive disease of retinal and choroidal vessels are found in patients with secondary APS. Patients with primary APS have also been reported to have ocular changes e.g. retinal vascular occlusion

The aim of our study to detect prevalence of ocular changes in women diagnosed with primary APS and correlation of these changes with adverse obstetric outcome. If a correlation is present, ocular findings in women with APS could be used in the future as a predictor for poor obstetric outcome.


Eligibility criteria: Inclusion Criteria:

* Age: 18 to 35 years
* Females with primary antiphospholipid syndrome

Exclusion Criteria:

* Age: below 18 years and above 35 years
* Auto-immune diseases e.g. SLE and other connective tissue disease
* Medical diseases causing retinal vascular changes e.g. hypertension, diabetes mellitus, sickle cell anemia.
* Previous vitreo-retinal surgery

Primary outcomes:
measure: The incidence of Ocular changes in females with antiphospholipid syndrome
timeFrame: On the same day of enrollment into the study
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
affiliation: Cairo University
name: Ahmed AA Wali, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03099408: Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent Recurrence of Bacterial Vaginosis
Official title: A Pilot Study of Efficacy and Safety of Oral Metronidazole Versus Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent the Recurrence of Bacterial Vaginosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Bacterial Vaginosis
Recurrence
Keywords: Recurrence
Lactobacillus Vaginal Suppositories
Lead sponsor: Peking University Shenzhen Hospital
Sponsor class: OTHER
First posted: 2017-04-04
Enrollment: 66
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 48
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We are trying to determine if Oral Metronidazole with Lactobacillus Vaginal Suppositories is better than Oral Metronidazole in Preventing the Recurrence of Bacterial Vaginosis

Detailed description: Bacterial vaginosis (BV) is the most prevalent cause of symptomatic vaginal discharge in the U.S. and has been associated with complications including preterm delivery of infants, pelvic inflammatory disease (PID), urinary tract infections (UTI) and acquisition/transmission of sexually transmitted diseases (STDs) including human immunodeficiency virus (HIV).

Control of BV has been advocated as a means of decreasing the prevalence of these complications. However, the etiology of BV remains unknown and the current treatment regimens are inadequate in terms of initial cure and recurrence rates.

Based on currently national guidelines by using oral metronidazole 400 BID for 7 days, a high recurrence rate of BV were reported.

We hypothesize that the Oral Metronidazole with Lactobacillus Vaginal Suppositories is better than Oral Metronidazole in Preventing the Recurrence of Bacterial Vaginosis

Eligibility criteria: Inclusion Criteria:

* Women be at least 18 years of age
* Have symptoms of vaginal odor and or/discharge
* Meet the clinical (Amsel) criteria for BV
* Willing to participate in research

Exclusion Criteria:

* Presence of another vaginal infection or STD
* Allergy to metronidazole
* Pregnant or nursing
* Use of oral or intravaginal antibiotics within the past 2 weeks
* HIV or other chronic disease
* Inability to keep return appointments
* Contraindications for Lactobacillus Vaginal Suppositories（those without sexual history）

Primary outcomes:
measure: Cure rate of BV
timeFrame: 4 weeks
Secondary outcomes:
measure: Recurrence of BV
timeFrame: 12 weeks
measure: Recurrence of BV
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Shenzhen
country: China
facility: Dept Obstetrics and Gynecology
state: Guangdong
Study officials:
affiliation: Peking University Shenzhen Hospital
name: Shangrong Fan, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Human Pathology in Adulthood and Childhood, University of Messina (Italy)
name: Salvatore Giovanni Vitale, M.D.
role: PRINCIPAL_INVESTIGATOR
References: